Fischer Medical Ventures rises on incorporating subsidiary
Fischer Medical Ventures is currently trading at Rs. 711.50, up by 1.75 points or 0.25% from its previous closing of Rs. 709.75 on the BSE.
The scrip opened at Rs. 725.00 and has touched a high and low of Rs. 725.00 and Rs. 706.00 respectively. So far 266 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 792.65 on 14-Jun-2024 and a 52 week low of Rs. 374.50 on 16-Feb-2024.
Last one week high and low of the scrip stood at Rs. 729.00 and Rs. 671.00 respectively. The current market cap of the company is Rs. 3778.71 crore.
The promoters holding in the company stood at 74.91% while Institutions and Non-Institutions held 6.75 % and 18.33 % respectively.
Fischer Medical Ventures has incorporated subsidiary namely Nanyang Biologics (India) on February 14, 2025. Nanyang Biologics (India) will engage in the business of manufacturing, formulating, importing, exporting, distributing, marketing, processing, and packaging of nutraceuticals, dietary supplements, functional foods, herbal supplements and other health related products for the promotion of human health. The company owns 51% of the shareholding in the new entity viz. Nanyang Biologics (India).
Fischer Medical Ventures is engaged in the trading of certain grades of Laboratory Chemicals.
